On July 23rd, 2026, the global therapy-focused healthcare group Fresenius SE & Co. KGaA formally announced the launch of its corporate venture capital fund, Fresenius Ventures. Earmarking an intended investment volume of more than €200 Million (approximately US$228 Million) over an initial five-year deployment period through July 2031, the unit establishes a strategic mechanism to systematically expand the group's access to external innovation networks. Designed to bridge ear